We are combatting the world’s largest killing epidemic of chronic disease. As a charitable organization, we are leading the path forward transforming large-scale public health. We have taken on the responsibility to uphold the public bringing the latest cutting-edge expertise and ground-breaking discoveries to the forefront for health.
The advancements of science have allowed us to discover the life-saving components of the human microbiome. It is changing the future of medicine – preventing disease – saving lives. Instead of waiting to treat patients after disease has developed, we now have the tools to personalize treatments and prevent disease before it even starts.
Due to the massive gap within the system, it takes an average of fifteen years for clinical care catch up with the science. When battling cancer, heart disease, and Alzheimer’s – patients don’t have fifteen years to wait.
What we do matters. We are closing the gap to prevent disease actively working with scientists, providers, payers, and most importantly the patients. We are tenaciously driven to heal the suffering – and to put an end to the silent killer.
COLLABORATION – Strength of the collective voice.
STRATEGY – Smart and strategic advancing public health.
INTEGRITY – Transparent and dedicated to saving lives.
ACTION – Intentional and relentless driving mission and vision.
ADVOCACY – Educate and empower millions to prevent disease.
A world of healthy microbiomes.
Dr. David P. Turner serves in the Division of Surgical Oncology at the NCI-designated Massey Comprehensive Cancer Center. He is Vice Chair of Research and Innovation in the Department of Surgery, Associate Professor in the School of Medicine at Virginia Commonwealth University. He also serves as Associate Director of Community Outreach and Engagement.
As Founder and President of the Anti-A.G.E. Foundation, Dr. Turner is internationally recognized for his leadership in cancer prevention research and education. His work centers on the role of advanced glycation end products (A.G.E.s)—a diverse group of reactive metabolites that arise from diet and lifestyle factors. The Turner Research Program is dedicated to demonstrating how increased bioavailability of A.G.E.s contributes to cancer development, treatment resistance, and disease progression.
Through his dual focus on research and community engagement, Dr. Turner is committed to translating scientific discovery into accessible education and practical strategies for cancer prevention. By bridging laboratory science with population health, he advances both innovation and equity in cancer care.
Dr. Victoria Findlay is an Associate Professor in the Department of Surgery and Co-Leader of the Cancer Prevention & Control Program at the NCI-designated Massey Comprehensive Cancer Center at Virginia Commonwealth University. She earned her BSc in Edinburgh, Scotland, and her PhD in Genetics at the University of Newcastle, England.
Dr. Findlay has dedicated her career to advancing women’s health and inspiring the next generation of scientists. Her research focuses on advanced glycation end products (A.G.E.s)—dietary metabolites with growing evidence of impact on cancer development and progression. She and her colleagues have uncovered significant links between A.G.E. metabolites and aggressive cancer outcomes, contributing to new understanding of how modifiable exposures may reduce cancer risk and improve disease management. Her investigations into the role of A.G.E.s in normal breast development highlight critical “windows of susceptibility” throughout a woman’s life that may influence breast cancer risk.
Beyond the laboratory, Dr. Findlay is deeply committed to public health education. Recognizing the importance of reaching diverse audiences, she co-founded the Anti-A.G.E.s Foundation, a nonprofit dedicated to raising global awareness of A.G.E.s and their health implications. Through this initiative, she and her team engage patients, community members, clinicians, and healthcare professionals with practical knowledge to empower informed health decisions and promote cancer prevention.
Through her combined efforts in research, education, and community engagement, Dr. Findlay is advancing a vision of healthier futures not only for women but for all individuals—bridging scientific discovery with real-world impact.
Dr. Burns C. Blaxall is Principal Consultant at PMG Insights, advising healthcare organizations and national health systems on optimizing the adoption of proactive precision medicine and value-based care.
He previously served as Senior Vice President of Precision Medicine at Aranscia, where he drove large-scale implementation of precision medicine strategies across health systems, payers, PBMs, employers, and provider networks.
Prior to that, he was the founding Executive Director of Precision Health at The Christ Hospital Health Network, where he built a nationally recognized program integrating hereditary risk screening, population health, and a pioneering pharmacogenomics (PGx) initiative. Under his leadership, the program launched one of the first prospective, randomized controlled trials of comprehensive PGx testing and achieved patient satisfaction scores in the 99th percentile.
Earlier in his career, Dr. Blaxall established and directed translational and clinical research centers, serving as principal investigator on numerous NIH and foundation grants. He has chaired NIH and foundation peer review panels and held editorial leadership positions for several scientific journals.
He earned his PhD in Pharmacology from the University of Colorado and has held academic and leadership appointments at Duke University, the University of Rochester, Cincinnati Children’s Hospital, and the University of Cincinnati, where he continues to serve as Adjunct Professor.
An elected fellow of multiple professional societies, Dr. Blaxall holds several patents, has delivered more than 200 invited lectures across six continents, and published nearly 100 peer-reviewed manuscripts.
He has received numerous honors and awards and continues to serve in leadership roles within professional societies and boards dedicated to precision medicine, pharmacogenomics, and therapeutic discovery.
Cassandra Isley founded the Microbiome Alliance for Disease Prevention after she, and her three daughters, were diagnosed with multiple, life-threatening, chronic diseases. In Cassandra’s early career she worked on the bench as a clinical laboratory scientist. She became Executive Director and Clinical Liaison overseeing multiple hospital divisions. For over 25 years, Cassandra has led strategic initiatives with global leaders in the healthcare, pharmaceutical, biotechnology, and life science industries.
MADP collaborative alliance is a convergence of strategic partners devoted to accelerating the microbiome ecosystem – TOGETHER. Our partners value the strategy of collaboration and the collective sharing of knowledge, expertise, and best practices to improving our nation’s health and the health of humanity across the globe.
